康方生物-B(09926-HK)亏损扩大2.8倍至13.21亿元
原标题：康方生物-B(09926-HK)亏损扩大2.8倍至13.21亿元
【财华社讯】康方生物-B(09926-HK)公布2020年度业绩，年内亏损扩大至13.21亿元(人民币。下同)，同比亏损扩大了281.2%；其中涉及非现金一次性可转换可赎回优先股的公允价变动3.15亿元。
期内收入为0.71亿元，来自收到与对外授权产品AK107有关的里程碑付款。其他收入及收益146%至1.235亿元，由于公司于联交所首次公开发售所得款项赚取的利息及当地政府对研发活动的补助增加。研发开支增加149.2%至7.686亿元，主要是由于临床试验发展及研发人员的数目及雇员薪金及相关福利成本(包括权益结算的股份奖励开支)增加导致的员工成本增加所致。
行政开支增加356.7%至2.53亿元，主要是由于与首次公开发售有关的上市开支增加、雇员薪金及福利(包括权益结算的股份奖励开支)增加以及非研发人员的数目增加所致。
港交所原文
（文章来源：财华社）
(责任编辑：DF544)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10